Imagerie par résonance magnétique de diffusion : Questions médicales fréquentes
Nom anglais: Diffusion Magnetic Resonance Imaging
Descriptor UI:D038524
Tree Number:E01.370.350.825.500.150
Termes MeSH sélectionnés :
Pilot Projects
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Imagerie par résonance magnétique de diffusion : Questions médicales les plus fréquentes",
"headline": "Imagerie par résonance magnétique de diffusion : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Imagerie par résonance magnétique de diffusion : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-01-08",
"dateModified": "2025-04-02",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Imagerie par résonance magnétique de diffusion"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Imagerie par résonance magnétique",
"url": "https://questionsmedicales.fr/mesh/D008279",
"about": {
"@type": "MedicalCondition",
"name": "Imagerie par résonance magnétique",
"code": {
"@type": "MedicalCode",
"code": "D008279",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "E01.370.350.825.500"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Imagerie par résonance magnétique de diffusion",
"alternateName": "Diffusion Magnetic Resonance Imaging",
"code": {
"@type": "MedicalCode",
"code": "D038524",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Christopher D Smyser",
"url": "https://questionsmedicales.fr/author/Christopher%20D%20Smyser",
"affiliation": {
"@type": "Organization",
"name": "Department of Neurology, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8111, St Louis, MO 63110-1093, USA; Department of Pediatrics, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8116, St Louis, MO 63110-1093, USA; Department of Radiology, Washington University School of Medicine, 660 South Euclid Avenue, Campus Box 8131, St Louis, MO 63110-1093, USA. Electronic address: smyserc@wustl.edu."
}
},
{
"@type": "Person",
"name": "Vincenza Granata",
"url": "https://questionsmedicales.fr/author/Vincenza%20Granata",
"affiliation": {
"@type": "Organization",
"name": "Division of Radiology, \"Istituto Nazionale Tumori IRCCS Fondazione Pascale-IRCCS di Napoli\", Naples, Italy."
}
},
{
"@type": "Person",
"name": "Roberta Fusco",
"url": "https://questionsmedicales.fr/author/Roberta%20Fusco",
"affiliation": {
"@type": "Organization",
"name": "Medical Oncology Division, Igea SpA, Napoli, Italy."
}
},
{
"@type": "Person",
"name": "Koji Kamagata",
"url": "https://questionsmedicales.fr/author/Koji%20Kamagata",
"affiliation": {
"@type": "Organization",
"name": "Department of Radiology, Juntendo University Graduate School of Medicine, Tokyo 113-8421, Japan."
}
},
{
"@type": "Person",
"name": "Christina Andica",
"url": "https://questionsmedicales.fr/author/Christina%20Andica",
"affiliation": {
"@type": "Organization",
"name": "Department of Radiology, Juntendo University Graduate School of Medicine, Tokyo 113-8421, Japan."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Compassion Fatigue and Spiritual Leaders: A Pilot Study.",
"datePublished": "2022-09-26",
"url": "https://questionsmedicales.fr/article/36164670",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1177/15423050221126099"
}
},
{
"@type": "ScholarlyArticle",
"name": "Evaluating the Impact of a Clinical Breast Examination Screening Program within the IraPEN Project.",
"datePublished": "2024-09-01",
"url": "https://questionsmedicales.fr/article/39342594",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.31557/APJCP.2024.25.9.3151"
}
},
{
"@type": "ScholarlyArticle",
"name": "The first Portuguese Open Dialogue pilot project intervention.",
"datePublished": "2023-09-07",
"url": "https://questionsmedicales.fr/article/37767212",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fpsyg.2023.1175700"
}
},
{
"@type": "ScholarlyArticle",
"name": "Evidence-based decision-making in nursing - development and piloting of a train-the-trainer concept for teachers at schools for health care professionals: A pilot study.",
"datePublished": "2022-10-31",
"url": "https://questionsmedicales.fr/article/36328933",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.zefq.2022.08.008"
}
},
{
"@type": "ScholarlyArticle",
"name": "Development of the Blackfeet Community Hospice Project: Pilot Workshop.",
"datePublished": "2022-08-16",
"url": "https://questionsmedicales.fr/article/35973208",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1177/10499091221121814"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Diagnostic",
"item": "https://questionsmedicales.fr/mesh/D003933"
},
{
"@type": "ListItem",
"position": 3,
"name": "Techniques et procédures diagnostiques",
"item": "https://questionsmedicales.fr/mesh/D019937"
},
{
"@type": "ListItem",
"position": 4,
"name": "Imagerie diagnostique",
"item": "https://questionsmedicales.fr/mesh/D003952"
},
{
"@type": "ListItem",
"position": 5,
"name": "Tomographie",
"item": "https://questionsmedicales.fr/mesh/D014054"
},
{
"@type": "ListItem",
"position": 6,
"name": "Imagerie par résonance magnétique",
"item": "https://questionsmedicales.fr/mesh/D008279"
},
{
"@type": "ListItem",
"position": 7,
"name": "Imagerie par résonance magnétique de diffusion",
"item": "https://questionsmedicales.fr/mesh/D038524"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Imagerie par résonance magnétique de diffusion - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Imagerie par résonance magnétique de diffusion",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-17",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Imagerie par résonance magnétique de diffusion",
"description": "Comment l'IRM de diffusion aide-t-elle au diagnostic ?\nQuels types de maladies sont détectables par IRM de diffusion ?\nL'IRM de diffusion est-elle utilisée pour le cancer ?\nPeut-on utiliser l'IRM de diffusion pour les maladies neurodégénératives ?\nL'IRM de diffusion est-elle efficace pour les lésions cérébrales ?",
"url": "https://questionsmedicales.fr/mesh/D038524?mesh_terms=Pilot+Projects&page=12#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Imagerie par résonance magnétique de diffusion",
"description": "Quels symptômes peuvent indiquer un besoin d'IRM de diffusion ?\nL'IRM de diffusion peut-elle aider à identifier des symptômes d'AVC ?\nQuels signes cliniques sont associés à des anomalies en IRM de diffusion ?\nLes troubles cognitifs peuvent-ils être évalués par IRM de diffusion ?\nL'IRM de diffusion peut-elle révéler des symptômes de tumeurs ?",
"url": "https://questionsmedicales.fr/mesh/D038524?mesh_terms=Pilot+Projects&page=12#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Imagerie par résonance magnétique de diffusion",
"description": "Comment l'IRM de diffusion contribue-t-elle à la prévention des AVC ?\nPeut-on utiliser l'IRM de diffusion pour le dépistage précoce ?\nQuels facteurs de risque peuvent être identifiés par IRM de diffusion ?\nL'IRM de diffusion peut-elle aider à prévenir les complications post-opératoires ?\nComment l'IRM de diffusion aide-t-elle à la gestion des maladies chroniques ?",
"url": "https://questionsmedicales.fr/mesh/D038524?mesh_terms=Pilot+Projects&page=12#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Imagerie par résonance magnétique de diffusion",
"description": "L'IRM de diffusion influence-t-elle les décisions de traitement ?\nPeut-on suivre l'évolution d'un traitement par IRM de diffusion ?\nL'IRM de diffusion est-elle utilisée avant une chirurgie ?\nQuels traitements peuvent être guidés par l'IRM de diffusion ?\nL'IRM de diffusion peut-elle aider à évaluer la nécessité d'une biopsie ?",
"url": "https://questionsmedicales.fr/mesh/D038524?mesh_terms=Pilot+Projects&page=12#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Imagerie par résonance magnétique de diffusion",
"description": "Quelles complications peuvent survenir après une IRM de diffusion ?\nL'IRM de diffusion peut-elle révéler des complications d'un AVC ?\nPeut-on détecter des complications liées à des tumeurs par IRM de diffusion ?\nL'IRM de diffusion peut-elle aider à prévenir des complications neurologiques ?\nQuelles complications peuvent être surveillées par IRM de diffusion ?",
"url": "https://questionsmedicales.fr/mesh/D038524?mesh_terms=Pilot+Projects&page=12#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Imagerie par résonance magnétique de diffusion",
"description": "Quels facteurs de risque sont associés aux AVC détectés par IRM de diffusion ?\nL'IRM de diffusion peut-elle identifier des facteurs de risque vasculaires ?\nQuels antécédents médicaux influencent les résultats de l'IRM de diffusion ?\nL'âge est-il un facteur de risque pour les anomalies détectées par IRM de diffusion ?\nLe mode de vie peut-il affecter les résultats de l'IRM de diffusion ?",
"url": "https://questionsmedicales.fr/mesh/D038524?mesh_terms=Pilot+Projects&page=12#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment l'IRM de diffusion aide-t-elle au diagnostic ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle permet de visualiser les zones de restriction de diffusion, souvent liées à des AVC."
}
},
{
"@type": "Question",
"name": "Quels types de maladies sont détectables par IRM de diffusion ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle détecte les AVC, les tumeurs, et les infections cérébrales."
}
},
{
"@type": "Question",
"name": "L'IRM de diffusion est-elle utilisée pour le cancer ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle aide à évaluer la réponse tumorale au traitement."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser l'IRM de diffusion pour les maladies neurodégénératives ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut aider à évaluer des maladies comme la sclérose en plaques."
}
},
{
"@type": "Question",
"name": "L'IRM de diffusion est-elle efficace pour les lésions cérébrales ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle permet de détecter des lésions subtiles non visibles par d'autres techniques."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un besoin d'IRM de diffusion ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des maux de tête sévères, des troubles de la vision ou des convulsions."
}
},
{
"@type": "Question",
"name": "L'IRM de diffusion peut-elle aider à identifier des symptômes d'AVC ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut montrer des zones de lésion correspondant aux symptômes d'AVC."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques sont associés à des anomalies en IRM de diffusion ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme la faiblesse musculaire ou des troubles de l'équilibre peuvent être observés."
}
},
{
"@type": "Question",
"name": "Les troubles cognitifs peuvent-ils être évalués par IRM de diffusion ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies peuvent être détectées chez les patients présentant des troubles cognitifs."
}
},
{
"@type": "Question",
"name": "L'IRM de diffusion peut-elle révéler des symptômes de tumeurs ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut montrer des zones de compression ou d'infiltration tumorale."
}
},
{
"@type": "Question",
"name": "Comment l'IRM de diffusion contribue-t-elle à la prévention des AVC ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle permet de détecter des signes précoces d'ischémie, facilitant une intervention rapide."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser l'IRM de diffusion pour le dépistage précoce ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut être utilisée pour le dépistage de maladies cérébrales chez les patients à risque."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque peuvent être identifiés par IRM de diffusion ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut révéler des anomalies vasculaires ou des lésions cérébrales liées à des facteurs de risque."
}
},
{
"@type": "Question",
"name": "L'IRM de diffusion peut-elle aider à prévenir les complications post-opératoires ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle permet de surveiller les complications potentielles après une chirurgie cérébrale."
}
},
{
"@type": "Question",
"name": "Comment l'IRM de diffusion aide-t-elle à la gestion des maladies chroniques ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle permet de surveiller l'évolution des maladies chroniques et d'ajuster les traitements."
}
},
{
"@type": "Question",
"name": "L'IRM de diffusion influence-t-elle les décisions de traitement ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle guide les choix thérapeutiques en fonction de la gravité des lésions."
}
},
{
"@type": "Question",
"name": "Peut-on suivre l'évolution d'un traitement par IRM de diffusion ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle permet d'évaluer la réponse au traitement au fil du temps."
}
},
{
"@type": "Question",
"name": "L'IRM de diffusion est-elle utilisée avant une chirurgie ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle aide à planifier les interventions chirurgicales en visualisant les lésions."
}
},
{
"@type": "Question",
"name": "Quels traitements peuvent être guidés par l'IRM de diffusion ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements pour les AVC, les tumeurs et les infections peuvent être guidés."
}
},
{
"@type": "Question",
"name": "L'IRM de diffusion peut-elle aider à évaluer la nécessité d'une biopsie ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut identifier des zones suspectes nécessitant une biopsie."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir après une IRM de diffusion ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications sont rares, mais peuvent inclure des réactions allergiques au contraste."
}
},
{
"@type": "Question",
"name": "L'IRM de diffusion peut-elle révéler des complications d'un AVC ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut montrer des zones de nécrose ou d'œdème post-AVC."
}
},
{
"@type": "Question",
"name": "Peut-on détecter des complications liées à des tumeurs par IRM de diffusion ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut identifier des complications comme l'infiltration tumorale ou l'œdème."
}
},
{
"@type": "Question",
"name": "L'IRM de diffusion peut-elle aider à prévenir des complications neurologiques ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle permet une détection précoce des anomalies pouvant entraîner des complications."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent être surveillées par IRM de diffusion ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle permet de surveiller des complications comme l'œdème cérébral ou les hémorragies."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont associés aux AVC détectés par IRM de diffusion ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'hypertension, le diabète et le tabagisme sont des facteurs de risque majeurs."
}
},
{
"@type": "Question",
"name": "L'IRM de diffusion peut-elle identifier des facteurs de risque vasculaires ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut montrer des anomalies vasculaires comme l'athérosclérose."
}
},
{
"@type": "Question",
"name": "Quels antécédents médicaux influencent les résultats de l'IRM de diffusion ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antécédents d'AVC ou de maladies cardiaques peuvent influencer les résultats."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque pour les anomalies détectées par IRM de diffusion ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque d'anomalies cérébrales augmente avec l'âge."
}
},
{
"@type": "Question",
"name": "Le mode de vie peut-il affecter les résultats de l'IRM de diffusion ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des habitudes comme le manque d'exercice et une mauvaise alimentation augmentent les risques."
}
}
]
}
]
}
This is a pilot study on compassion fatigue experienced by spiritual leaders. The sample consisted of 15 religious affiliations with a total of 41 participants (30 males and 11 females). In this sampl...
Breast cancer is a prevalent global cancer and a leading cause of mortality in developed countries. In 2015, Iran introduced the Package of Essential Noncommunicable Diseases (IraPEN) as a pilot proje...
This descriptive cost-outcome study utilized data from 450,876 individuals aged 30 to 69 who participated in clinical breast examination screening. The outcomes assessed in this program encompassed th...
The findings revealed that the direct costs of the breast cancer screening program in Isfahan between 2017 and 2020 were 310,514,608,558 Rials, equivalent to approximately 15,470,633 PPP$. These expe...
This study demonstrates that the breast cancer screening program provides a significant number of women in the target age group with breast self-examination education while raising public awareness ab...
In 2020, the Directorate General of Health (DGS), a central service of the Ministry of Health in Portugal, approved and co-financed the first Open Dialogue program in the country. The present report a...
Seven people at the Center of Concern (PCC) and 21 family members/social networks received care through Open Dialogue; four external social workers and psychologists were also involved in the project ...
The preliminary results indicate an improvement in global functioning and the enlargement of social network size/support, a decrease in symptoms, and a negative correlation between the number of sessi...
In general, even with a small sample, the results are considered satisfactory and seem to be aligned with the vast majority of Open Dialogue studies, which for several decades have consistently pointe...
Train-the-trainer concepts (TTT concepts) to impart evidence-based practice competences aim at promoting the implementation of evidence-based practice. The aim of this study was to develop and pilot-t...
The study was conducted according to the UKMRC framework for complex interventions and consisted of Phase 1 (Development) and Phase 2 (Piloting). In Phase 1, the intervention was modelled on the basis...
Piloting took place in September 2018 and from September to November 2019. Eight teachers from two training institutions participated. The evaluation of the focus group interviews and the classroom ob...
Using mixed methods, the results show the feasibility of the curriculum....
Further evaluation in a randomized controlled trial (RCT) is needed to prove the efficacy of the curriculum....
Taboo perception on talking about death and dying among American Indians/Alaska Natives is prevalent. This suppressive value makes hospice introduction difficult, leading hospice disparity. Working to...
Many people with opioid use disorder who stand to benefit from buprenorphine treatment are unwilling to initiate it due to experience with or fear of both spontaneous and buprenorphine-precipitated op...
Patients prescribed ketamine were either (1) seeking transition to buprenorphine from illicit fentanyl and highly apprehensive of BPOW or (2) undergoing transition to buprenorphine from illicit fentan...
Over a period of 14 months, 37 patients were prescribed ketamine. Buprenorphine initiation was completed by 16 patients, representing 43% of the 37 patients prescribed ketamine, and 67% of the 24 who ...
Ketamine at a sub-dissociative dose allowed completion of buprenorphine initiation in the outpatient setting in the majority of patients who reported trying it. Further research is warranted to confir...
Doctors in the UK experience significant heterogeneity in training. Whilst core curricula underpin specialty training, diversity in clinical attachments results in a heterogeneous knowledge base and v...
To aggregate examples of such clinical insights; To assess the extent of recommendation and evidence for these insights; To raise awareness of underutilised clinical insights, to highlight areas for f...
A qualitative survey seeking free text responses, open to all UK healthcare professionals, was disseminated opportunistically. Responses were recorded and the insights were assessed against the existi...
29 clinical insights were collated across multiple specialties. Some already formed part of national guidance, but appeared to be underutilised, while others appeared only in local or international gu...
We uncovered a range of lesser-known clinical insights across a range of specialties, as well as some less well-evidenced practices. Many insights have the potential to positively impact patient care,...
Targeting the parasympathetic nervous system innervating the airway with pharmacologic products has been proved to improve the clinical outcomes of severe asthma. Bronchial cryo-denervation (BCD) is a...
A total of 15 patients with severe asthma were enrolled in this prospective, single-center pilot study. Patients underwent bifurcated BCD treatment at a 30-day interval after baseline assessment. Foll...
BCD was performed on all 15 severe asthma patients, with technical feasibility of 96.7%. There were no device-related and 2 procedure-related serious adverse events through 12 months, which resolved w...
This study provides the first clinical evidence of the safety, feasibility, and initial efficacy of BCD in patients with severe asthma....
Neurodegenerative diseases often alter sleep architecture, complicating the application of the standard sleep scoring rules. There are no recommendations to overcome this problem. Our aim was to devel...
Video-polysomnographies (VPSG) of nine patients (DLB:3, Parkinson's disease (PD):3, and multiple system atrophy (MSA):3) selected for their difficulty in applying standard rules were scored independen...
Patients (4 females) had a median age of 74 (range 63-85). Six patients (all with PD or DLB) had abnormal EEG awake and Subwake stage. UNREM sleep was present in all patients, typically at sleep onset...
Our scoring system allows an accurate description of the complex sleep-wake changes in patients with alpha-synucleinopathies....
The precise effects of non-steroidal anti-inflammatory drugs on the neuroendocrine hydro-electrolytic regulation are not precisely understood. The aim of this pilot study was to evaluate, in healthy s...
For this single-blinded, cross-over study, we recruited 12 healthy subjects (50% women). Test sessions were divided into three observation times (pre-test; test; 48 h post-test), which were repeated e...
No significant changes in circulating hormone levels were observed; anyway, 48 h after diclofenac, BIVA showed a significant water retention (p < 0.00001), especially in extracellular fluid (ECF) (16....
Diclofenac resulted in an increased ECF at 48 h, but this phenomenon seems to be associated with a greater renal sensibility to the action of vasopressin rather than with an increase in its secretion....